Cellares Announced That Bristol Myers Squibb Will Enter A Second Proof-of-concept Tech Transfer Process For The Manufacture Of A CAR-T Cell Therapy, As Part Of The Cellares Technology Adoption Partnership Program
Portfolio Pulse from Benzinga Newsdesk
Cellares has announced that Bristol Myers Squibb (BMY) will enter a second proof-of-concept tech transfer process for the manufacture of a CAR-T cell therapy. This is part of the Cellares Technology Adoption Partnership Program, where Cellares will optimize, automate, and tech-transfer the additional CAR-T cell therapy process onto its automated manufacturing platform, the Cell Shuttle.
October 11, 2023 | 11:04 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bristol Myers Squibb is entering a second tech transfer process with Cellares for CAR-T cell therapy manufacture, which could potentially enhance its product portfolio and manufacturing efficiency.
The news of Bristol Myers Squibb entering a second tech transfer process with Cellares for CAR-T cell therapy manufacture is directly relevant to the company. This could potentially enhance its product portfolio and manufacturing efficiency, which could positively impact its stock in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100